ClinicalTrials.gg
RecruitingNCT05953038dOccLSUpdated Nov 16, 2026

LSD Occupancy of the Serotonin 2A Receptor in the Human Brain

An Early Phase 1 interventional study of Lysergic Acid Diethylamide Tartrate in Basic Science, sponsored by Copenhagen University Hospital, Rigshospitalet. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Copenhagen University Hospital, Rigshospitalet · Early Phase 1, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Nov 16, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission tomography.

Read the detailed description

Healthy participants will be administered one of a single dose of lysergic acid diethylamide (LSD) between 25 and 200 micrograms equivalent freebase. They will receive [11C]CIMBI-36 positron emission tomography (PET) scans at baseline and twice following LSD administration during peak and declining drug effects. PET scans will be acquired in a simultaneous PET/Magnetic Resonance Imaging (MRI) scanner which will also collect functional brain imaging data. Venous blood samples will be repeatedly drawn during acute drug effects for quantification of plasma LSD levels. Participants will also repeatedly rate their subjective drug intensity on a scale from 0 to 10 during acute drug effects. Together these data will inform the dose-binding relation of LSD at the serotonin (5-HT) 2A receptor, the primary site of action. This data will also inform the relation between 5-HT2A receptor binding by LSD and the induced subjective effects, as well as the effects on functional brain activity as measured with functional MRI.

02

Conditions studied

  • Basic Science

Keywords

  • Lysergic acid diethylamide
  • PET
  • Psychedelic
  • Hallucinogen
  • Physiological Effects of Drugs
  • Psychotropic Drugs
  • Ergolines
  • Serotonin
  • Serotonin Agents
  • Neurotransmitter Agents
  • Molecular Mechanisms of Pharmacological Action
03

In context

Lead sponsor

Copenhagen University Hospital, Rigshospitalet is the lead sponsor of 46 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy individual between 18-75 years old

Exclusion criteria

Exclusion Criteria:

  • Current or past history of primary psychiatric illness (The IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification)
  • Current or past history of primary psychiatric illness (The Diagnostic and Statistical Manual of Mental Disorders IV axis-I or World Health Organisation International Classification of Diseases-10 diagnostic classification) in a first degree relative (i.e., parents, siblings)
  • Current or past history of neurological disease, significant somatic condition/disease
  • Use of medication that could potentially influence results (e.g.., drugs that act on relevant components of the serotonin system or may interfere with metabolism of study drug)
  • Non-fluent Danish language skills
  • Profound visual or auditory impairments
  • Severe learning disability
  • Pregnancy on the scan date, verified by a pregnancy test (test omitted if confirmed that individual is )
  • Lactation (females)
  • for magnetic resonance imaging (e.g., pacemaker, claustrophobia, etc.)
  • Contraindications for positron emission tomography
  • Alcohol or drug abuse
  • Allergy to administered compounds
  • Participant in research study with >10 millisievert exposure within the past year or significant occupational exposure to radioactive substances
  • Abnormal (ECG indicating current or previous heart disease or predisposition to heart disease, e.g., ) or use of QT prolonging medication
  • Use of psychedelic substance within the preceding six months
  • Blood donation up to three months before the study (i.e., more than 500ml of blood)
  • Head injury or concussion resulting in loss of consciousness for more than 2 min
  • levels \< 7.8 mmol/l for women and 8.4 mmol/l for men
  • Ferritin levels outside normal range (12-300 µg/L)
  • Body-weight \< 50 kg or > 110kg
  • body-mass index > 35
  • Individual assessment by research staff deeming drug administration unsafe due to ethical or psychological circumstance of the participant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    LSD dose-ranging group

    All participants will receive between 25 and 200 micrograms of lysergic acid diethylamide equivalent as freebase, single blinded with respect to dose. Simultaneous PET/MR imaging will be performed during acute drug effects.

    Drug: Lysergic Acid Diethylamide Tartrate

Interventions

06

What researchers measure

Primary outcomes

  1. Plasma LSD - serotonin 2A receptor (5-HT2AR) occupancy relation

    Occupancy will be estimated by comparing non-displaceable binding potential (BPND) values using baseline and intervention rescans as calculated using a simplified reference tissue model (SRTM). Occupancy values will be compared to plasma lysergic acid diethylamide (LSD) levels.

    Time frame: Within 24 hours following drug administration

Secondary outcomes

  1. Subjective drug intensity - 5-HT2AR occupancy relation

    Occupancy will be calculated as described above. Subjective drug intensity is collected during positron emission tomography (PET) scans by asking participants.

    Time frame: Within 24 hours following drug administration

  2. fMRI network disintegration - 5-HT2AR occupancy relation

    functional magnetic resonance imaging (fMRI) data will be used to estimate functional-network connectivity using a standard functional brain atlas. Then the relation between decreases in functional network connectivity and 5-HT2AR occupancy will be estimated.

    Time frame: Within 24 hours following drug administration

  3. fMRI brain entropy - 5-HT2AR occupancy relation

    fMRI brain entropy will be estimated by the shannon entropy of dynamic conditional correlation of within and between network connectivity as well as the lempel-ziv complexity of concatenated binarised blood-oxygen level dependent (BOLD) signals across regions. The relation between each of these measures with 5-HT2AR occupancy will be estimated.

    Time frame: Within 24 hours following drug administration

  4. Cerebral perfusion - 5-HT2AR occupancy relation

    Cerebral perfusion will be estimated using arterial spin labelling. The relation between this measure and 5-HT2AR occupancy will be estimated.

    Time frame: Within 24 hours following drug administration

  5. Administered LSD dose - 5-HT2AR occupancy relation

    Administered dose (25 to 200 mcg) will be compared with peak LSD occupancy to determine what doses produce maximal occupancy at the 5-HT2AR.

    Time frame: Within 24 hours following drug administration

Other outcomes

  1. Hysteresis effect of 5-HT2AR binding

    Estimated dose-occupancy curves derived from the first PET scan and second PET scan will be calculated separately to evaluate whether there are differences in estimated plasma level-occupancy relation at different timepoints following LSD administration which may indicate a hysteresis effect due to peripheral LSD metabolism without unbinding of LSD from the 5-HT2A receptor.

    Time frame: Within 24 hours following drug administration

07

Study locations

1 of 1 sites recruiting
  • Neurobiology Research Unit, Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
    • Gitte M Knudsen, DMSc · Contactgmk@nru.dk · +45 35456720
    • Drummond E. McCulloch, BSc · Sub investigator
    • Patrick M. Fisher, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Dec 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2023
First posted
Jul 19, 2023
StartActual
Nov 8, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 16, 2026
Sites
Neurobiology Research Unit, Rigshospitalet is now Recruiting
Nov 16, 2026
Contact
Study contact now listed: added g•••@nru.dk · •••6720; added p•••@nru.dk · •••6714. See the current contact
Nov 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Neurobiology Research Unit, Rigshospitalet · Copenhagen, DenmarkContact added g•••@nru.dk · •••6720Contact added (no phone or email listed)Contact added (no phone or email listed)
Nov 16, 2026
Sponsor
Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Active, not recruiting→Recruiting
    Neurobiology Research Unit, Rigshospitalet is now Recruiting
    Sponsor Rigshospitalet, Denmark→Copenhagen University Hospital, Rigshospitalet
    Contact Study contact now listed: added g•••@nru.dk · •••6720; added p•••@nru.dk · •••6714. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Neurobiology Research Unit, Rigshospitalet · Copenhagen, DenmarkContact added g•••@nru.dk · •••6720Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05953038
Lead sponsor
Copenhagen University Hospital, Rigshospitalet
Responsible party
Gitte Moos Knudsen (Professor, DMsc, MD, Copenhagen University Hospital, Rigshospitalet) — Principal investigator
First posted
Jul 19, 2023
Start date
Nov 8, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Gitte M Knudsen, DMsc, MD
Contact
gmk@nru.dk
35456720 ext. +45
Patrick M Fisher, PhD
Contact
patrick.fisher@nru.dk
35456714 ext. +45
Gitte M Knudsen, DMsc, MD
principal investigator · Copenhagen University Hospital, Rigshospitalet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lysergic Acid Diethylamide

Start the discussion